Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	New Amedeo service: Amedeo COVID-19 (formerly 2019-nCoV) Weekly publication summary

Breast Cancer

Free Subscription 16.12.2019 2 Ann Surg Oncol 1 Anticancer Res 4 Br J Cancer 4 Breast Cancer 3 Breast Cancer Res 2 Breast Cancer Res Treat 1 Breast J 1 Cancer 1 Cancer Res 2 Clin Cancer Res 1 Eur J Cancer 2 Eur Radiol 1 Exp Cell Res 3 J Clin Oncol 2 Lancet 3 N Engl J Med 2 NPJ Breast Cancer 1 Oncogene 1 PLoS Comput Biol 5 PLoS One 1 Proc Natl Acad Sci U S A 1 Radiology

Retrieve available abstracts of this week’s articles: HTML format Text format

Single Articles

Ann Surg Oncol

1. VALERO MG, Muhsen S, Moo TA, Zabor EC, et al
   Increase in Utilization of Nipple-Sparing Mastectomy for Breast Cancer: Indications, Complications, and Oncologic Outcomes.
   Ann Surg Oncol. 2019 Dec 10. pii: 10.1245/s10434-019-07948.
   PubMed     Text format     Abstract available
   
   
2. SILVA E, Tan M
   ASO Author Reflections: Why the Surgeon, Who is the Person Most Influential in the Management of Breast Cancer, Must Have a Multidisciplinary Mindset.
   Ann Surg Oncol. 2019 Dec 6. pii: 10.1245/s10434-019-08053.
   PubMed     Text format    
   
   

   
   Anticancer Res

3. OTA D, Akatsuka S, Nishi T, Kato T, et al
   Phase I Study of Combination Therapy With Weekly Nanoparticle Albumin-bound Paclitaxel and Cyclophosphamide in Metastatic Breast Cancer Patients.
   Anticancer Res. 2019;39:6903-6907.
   PubMed     Text format     Abstract available
   
   

   
   Br J Cancer

4. LORD SR, Collins JM, Cheng WC, Haider S, et al
   Transcriptomic analysis of human primary breast cancer identifies fatty acid oxidation as a target for metformin.
   Br J Cancer. 2019 Dec 10. pii: 10.1038/s41416-019-0665.
   PubMed     Text format     Abstract available
   
   
5. ANSARI RE, Craze ML, Althobiti M, Alfarsi L, et al
   Enhanced glutamine uptake influences composition of immune cell infiltrates in breast cancer.
   Br J Cancer. 2019 Dec 10. pii: 10.1038/s41416-019-0626.
   PubMed     Text format     Abstract available
   
   
6. SOLA-PENNA M, Paixao LP, Branco JR, Ochioni AC, et al
   Serotonin activates glycolysis and mitochondria biogenesis in human breast cancer cells through activation of the Jak1/STAT3/ERK1/2 and adenylate cyclase/PKA, respectively.
   Br J Cancer. 2019 Dec 10. pii: 10.1038/s41416-019-0640.
   PubMed     Text format     Abstract available
   
   
7. KAWASHIMA M, Tokiwa M, Nishimura T, Kawata Y, et al
   High-resolution imaging mass spectrometry combined with transcriptomic analysis identified a link between fatty acid composition of phosphatidylinositols and the immune checkpoint pathway at the primary tumour site of breast cancer.
   Br J Cancer. 2019 Dec 10. pii: 10.1038/s41416-019-0662.
   PubMed     Text format     Abstract available
   
   

   
   Breast Cancer

8. INOKUCHI M, Kutomi G, Kijima Y, Sakai T, et al
   The Japanese Breast Cancer Society clinical practice guidelines for surgical treatment of breast cancer, 2018 edition.
   Breast Cancer. 2019 Dec 12. pii: 10.1007/s12282-019-01030.
   PubMed     Text format     Abstract available
   
   
9. HASHEMI SM, Rafiemanesh H, Aghamohammadi T, Badakhsh M, et al
   Prevalence of anxiety among breast cancer patients: a systematic review and meta-analysis.
   Breast Cancer. 2019 Dec 11. pii: 10.1007/s12282-019-01031.
   PubMed     Text format     Abstract available
   
   
10. KISHINO E, Ogata R, Saitoh W, Koike Y, et al
    Anti-cell growth and anti-cancer stem cell activity of the CDK4/6 inhibitor palbociclib in breast cancer cells.
    Breast Cancer. 2019 Dec 10. pii: 10.1007/s12282-019-01035.
    PubMed     Text format     Abstract available
    
    
11. KAWAGUCHI H, Masuda N, Nakayama T, Aogi K, et al
    Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study.
    Breast Cancer. 2019 Dec 6. pii: 10.1007/s12282-019-01029.
    PubMed     Text format     Abstract available
    
    

    
    Breast Cancer Res

12. SHEN Q, Joud A, Schelin MEC, Sjolander A, et al
    Psychiatric disorders and cardiovascular diseases during the diagnostic workup of potential breast cancer: a population-based cohort study in Skane, Sweden.
    Breast Cancer Res. 2019;21:139.
    PubMed     Text format     Abstract available
    
    
13. SINN BV, Weber KE, Schmitt WD, Fasching PA, et al
    Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy.
    Breast Cancer Res. 2019;21:142.
    PubMed     Text format     Abstract available
    
    
14. GOLDHAMMER N, Kim J, Timmermans-Wielenga V, Petersen OW, et al
    Characterization of organoid cultured human breast cancer.
    Breast Cancer Res. 2019;21:141.
    PubMed     Text format     Abstract available
    
    

    
    Breast Cancer Res Treat

15. KIM MH, Kim GM, Kim JH, Kim JY, et al
    Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55 years and older.
    Breast Cancer Res Treat. 2019 Dec 6. pii: 10.1007/s10549-019-05505.
    PubMed     Text format     Abstract available
    
    
16. HEUBLEIN S, Egger M, Zhu J, Berger L, et al
    Evaluation of the anti-Thomsen-Friedenreich antibodies Nemod-TF1 and Nemod-TF2 as prognostic markers in breast cancer.
    Breast Cancer Res Treat. 2019 Dec 11. pii: 10.1007/s10549-019-05503.
    PubMed     Text format     Abstract available
    
    

    
    Breast J

17. WANG L, Gao S, Li D, Ran X, et al
    CDK4/6 inhibitors plus endocrine therapy improve overall survival in advanced HR+/HER2- breast cancer: A meta-analysis of randomized controlled trials.
    Breast J. 2019 Dec 11. doi: 10.1111/tbj.13703.
    PubMed     Text format    
    
    

    
    Cancer

18. HUMPHRIES B, Lauzier S, Drolet M, Coyle D, et al
    Wage losses among spouses of women with nonmetastatic breast cancer.
    Cancer. 2019 Dec 10. doi: 10.1002/cncr.32638.
    PubMed     Text format     Abstract available
    
    

    
    Cancer Res

19. MOYER CL, Ivanovich J, Gillespie JL, Doberstein R, et al
    Rare BRIP1 missense alleles confer risk for ovarian and breast cancer.
    Cancer Res. 2019 Dec 10. pii: 0008-5472.CAN-19-1991.
    PubMed     Text format     Abstract available
    
    

    
    Clin Cancer Res

20. LEHMANN BD, Abramson VG, Sanders M, Mayer EL, et al
    TBCRC 032 IB/II Multicenter Study: Molecular insights to AR antagonist and PI3K inhibitor efficacy in patients with AR+ metastatic triple-negative breast cancer.
    Clin Cancer Res. 2019 Dec 10. pii: 1078-0432.CCR-19-2170.
    PubMed     Text format     Abstract available
    
    
21. PAGE DB, Pucilowska J, Sanchez KG, Conlin AK, et al
    A phase Ib study of pre-operative, locoregional IRX-2 cytokine immunotherapy to prime immune responses in patients with early stage breast cancer.
    Clin Cancer Res. 2019 Dec 12. pii: 1078-0432.CCR-19-1119.
    PubMed     Text format     Abstract available
    
    

    
    Eur J Cancer

22. PASQUIER D, Darlix A, Louvel G, Fraisse J, et al
    Treatment and outcomes in patients with central nervous system metastases from breast cancer in the real-life ESME MBC cohort.
    Eur J Cancer. 2019;125:22-30.
    PubMed     Text format     Abstract available
    
    

    
    Eur Radiol

23. RODRIGUEZ-RUIZ A, Lang K, Gubern-Merida A, Teuwen J, et al
    Can we reduce the workload of mammographic screening by automatic identification of normal exams with artificial intelligence? A feasibility study.
    Eur Radiol. 2019;29:4825-4832.
    PubMed     Text format     Abstract available
    
    
24. CELEBI F, Agacayak F, Ozturk A, Ilgun S, et al
    Usefulness of imaging findings in predicting tumor-infiltrating lymphocytes in patients with breast cancer.
    Eur Radiol. 2019 Dec 10. pii: 10.1007/s00330-019-06516.
    PubMed     Text format     Abstract available
    
    

    
    Exp Cell Res

25. LI Q, Cao J, He Y, Liu X, et al
    R5, a neutralizing antibody to Robo1, suppresses breast cancer growth and metastasis by inhibiting angiogenesis via down-regulating filamin A.
    Exp Cell Res. 2019 Dec 4:111756. doi: 10.1016/j.yexcr.2019.111756.
    PubMed     Text format     Abstract available
    
    

    
    J Clin Oncol

26. DUMAS A, Vaz Luis I, Bovagnet T, El Mouhebb M, et al
    Impact of Breast Cancer Treatment on Employment: Results of a Multicenter Prospective Cohort Study (CANTO).
    J Clin Oncol. 2019 Dec 13:JCO1901726. doi: 10.1200/JCO.19.01726.
    PubMed     Text format     Abstract available
    
    
27. FEHRENBACHER L, Cecchini RS, Geyer CE Jr, Rastogi P, et al
    NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2.
    J Clin Oncol. 2019 Dec 10:JCO1901455. doi: 10.1200/JCO.19.01455.
    PubMed     Text format     Abstract available
    
    
28. TAMURA K, Imamura CK, Takano T, Saji S, et al
    CYP2D6 Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study.
    J Clin Oncol. 2019 Dec 10:JCO1901412. doi: 10.1200/JCO.19.01412.
    PubMed     Text format     Abstract available
    
    

    
    Lancet

29. WHELAN TJ, Julian JA, Berrang TS, Kim DH, et al
    External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial.
    Lancet. 2019 Dec 5. pii: S0140-6736(19)32515.
    PubMed     Text format     Abstract available
    
    
30. VICINI FA, Cecchini RS, White JR, Arthur DW, et al
    Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial.
    Lancet. 2019 Dec 5. pii: S0140-6736(19)32514.
    PubMed     Text format     Abstract available
    
    

    
    N Engl J Med

31. SLAMON DJ, Neven P, Chia S, Fasching PA, et al
    Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.
    N Engl J Med. 2019 Dec 11. doi: 10.1056/NEJMoa1911149.
    PubMed     Text format     Abstract available
    
    
32. MODI S, Saura C, Yamashita T, Park YH, et al
    Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.
    N Engl J Med. 2019 Dec 11. doi: 10.1056/NEJMoa1914510.
    PubMed     Text format     Abstract available
    
    
33. MURTHY RK, Loi S, Okines A, Paplomata E, et al
    Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
    N Engl J Med. 2019 Dec 11. doi: 10.1056/NEJMoa1914609.
    PubMed     Text format     Abstract available
    
    

    
    NPJ Breast Cancer

34. EXMAN P, Mallery RM, Lin NU, Parsons HA, et al
    Response to Olaparib in a Patient with Germline BRCA2 Mutation and Breast Cancer Leptomeningeal Carcinomatosis.
    NPJ Breast Cancer. 2019;5:46.
    PubMed     Text format     Abstract available
    
    
35. ZIEGLER Y, Laws MJ, Sanabria Guillen V, Kim SH, et al
    Suppression of FOXM1 activities and breast cancer growth in vitro and in vivo by a new class of compounds.
    NPJ Breast Cancer. 2019;5:45.
    PubMed     Text format     Abstract available
    
    

    
    Oncogene

36. LI K, Zhang J, Tian Y, He Y, et al
    The Wnt/beta-catenin/VASP positive feedback loop drives cell proliferation and migration in breast cancer.
    Oncogene. 2019 Dec 12. pii: 10.1038/s41388-019-1145.
    PubMed     Text format     Abstract available
    
    

    
    PLoS Comput Biol

37. KONIG SM, Rissler V, Terkelsen T, Lambrughi M, et al
    Alterations of the interactome of Bcl-2 proteins in breast cancer at the transcriptional, mutational and structural level.
    PLoS Comput Biol. 2019;15:e1007485.
    PubMed     Text format     Abstract available
    
    

    
    PLoS One

38. PARK HS, Lee JD, Kim JY, Park S, et al
    Establishment of chemosensitivity tests in triple-negative and BRCA-mutated breast cancer patient-derived xenograft models.
    PLoS One. 2019;14:e0225082.
    PubMed     Text format     Abstract available
    
    
39. JOGI A, Ehinger A, Hartman L, Alkner S, et al
    Expression of HIF-1alpha is related to a poor prognosis and tamoxifen resistance in contralateral breast cancer.
    PLoS One. 2019;14:e0226150.
    PubMed     Text format     Abstract available
    
    
40. WEN W, Xuan D, Hu Y, Li X, et al
    Prognostic value of maximum standard uptake value, metabolic tumor volume, and total lesion glycolysis of positron emission tomography/computed tomography in patients with breast cancer: A systematic review and meta-analysis.
    PLoS One. 2019;14:e0225959.
    PubMed     Text format     Abstract available
    
    
41. 
    Retraction: Ramentaceone, a Naphthoquinone Derived from Drosera sp., Induces Apoptosis by Suppressing PI3K/Akt Signaling in Breast Cancer Cells.
    PLoS One. 2019;14:e0226703.
    PubMed     Text format    
    
    
42. YOO B, Meka N, Sheedy P, Billig AM, et al
    MicroRNA-710 regulates multiple pathways of carcinogenesis in murine metastatic breast cancer.
    PLoS One. 2019;14:e0226356.
    PubMed     Text format     Abstract available
    
    

    
    Proc Natl Acad Sci U S A

43. FU X, Pereira R, De Angelis C, Veeraraghavan J, et al
    FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer.
    Proc Natl Acad Sci U S A. 2019 Dec 11. pii: 1911584116.
    PubMed     Text format     Abstract available
    
    

    
    Radiology

44. HOVDA T, Holen AS, Lang K, Albertsen JL, et al
    Interval and Consecutive Round Breast Cancer after Digital Breast Tomosynthesis and Synthetic 2D Mammography versus Standard 2D Digital Mammography in BreastScreen Norway.
    Radiology. 2019 Dec 10:191337. doi: 10.1148/radiol.2019191337.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: